Servier laying off 610 workers; China looks inward for biopharma growth;

@FierceBiotech: Star fund manager Woodford calls in ex-FBI agent to probe Northwest Bio allegations. Report | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers gets elotuzumab OK for multiple myeloma -- Believe that makes 39 for the year so far. More | Follow @JohnCFierce

@DamianFierce: Actually, inversions are ... good? More from the NYT | Follow @DamianFierce

> Servier is plotting major staffing cuts in its native France, looking to lay off 610 workers in response to sluggish sales. News

> China is ramping up its efforts to grow a local biopharma industry, reforming its regulatory structure to encourage in-country companies to compete with multinationals. More

> Merck KGaA plans to launch a new drug every year from 2017 forward, incoming CEO Stefan Oschmann said, starting with a Pfizer ($PFE)-partnered cancer immunotherapy. Story

Medical Device News

@FierceMedDev: ICYMI: Scientists make strides with real-time estrogen sensor. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Entellus wins FDA clearance for its endoscope to treat blocked sinus passages. Story | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Valeant's 18-fold price hikes top widespread increases in dermatology prices. FiercePharma story | Follow @EmilyWFierce

> Wright Medical slapped with $11M verdict in bellwether case over metal hip implant. More

> Novartis' Alcon recalling more intraocular lenses due to reports of postoperative inflammation. Article

Pharma News

@FiercePharma: Report: Sanofi cooking up $12.7B animal health spinoff. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMIFDA warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Trump, Clinton lash out at Pfizer over Allergan deal. Article | Follow @CarlyHFierce

> Servier plots major layoffs in France after R&D setbacks, payer cuts. Story

> JAMA: Valeant's 18-fold price hikes top widespread increases in dermatology prices. More

> GSK's anticorruption overhaul in China may be hobbling sales. Article

Pharma Marketing News

> What caught our readers' fancy this year? Here's your top 10 FiercePharmaMarketing capsule. Editor's corner

> Amgen slaps $178K price on rare new leukemia drug Blincyto. More

> Top cancer doc takes to social media to fight rising prices. More

> Are Glaxo's China sales reforms putting it at a commercial disadvantage? More

> Big Pharma's bad rap made late-night TV, even before the Shkreli effect. More

Animal Health News

> Scientists roll out innovative health-tracking device for guide dogs. Report

> Report: Sanofi cooking up $12.7B animal health spinoff. Story

> Merck and Zoetis line up rival vaccines to fight new strain of dog flu. More

> Nexvet focuses first investor symposium on prospects for biotech in vet medicine. Article

> Petco abandons IPO plan in favor of $4.6B buyout. Item

Biotech IT News

> U.K. commits a further $375M to 100,000 Genomes Project. News

> Pfizer-Allergan merger raises questions about future of NuMedii deal. Item

> MediSapiens applies bioinformatics to find ideal leukemia treatment regimens. Report

> With PhIII trial coming up, Infinity strikes risk-based monitoring deal with Medidata. Story

> BGI slams brakes on Revolocity rollout, lays off staff in business rethink. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.